story of the week
First-Line Nivolumab Plus Chemotherapy vs Chemotherapy Alone for Advanced Gastric, Gastro-Oesophageal Junction, and Oesophageal Adenocarcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
First-Line Nivolumab Plus Chemotherapy Versus Chemotherapy Alone for Advanced Gastric, Gastro-Oesophageal Junction, and Oesophageal Adenocarcinoma (CheckMate 649): A Randomised, Open-Label, Phase 3 Trial
Lancet 2021 Jun 04;[EPub Ahead of Print], YY Janjigian, K Shitara, M Moehler, M Garrido, P Salman, L Shen, L Wyrwicz, K Yamaguchi, T Skoczylas, A Campos Bragagnoli, T Liu, M Schenker, P Yanez, M Tehfe, R Kowalyszyn, MV Karamouzis, R Bruges, T Zander, R Pazo-Cid, E Hitre, K Feeney, JM Cleary, V Poulart, D Cullen, M Lei, H Xiao, K Kondo, M Li, JA AjaniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.